PriceTargets.com logo

Leap Therapeutics - LPTX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.38
  • Forecasted Upside: 255.47%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$3.20 As of 04/25/2024 04:51 PM ET
▼ -0.09 (-2.74%)

This chart shows the closing price for LPTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Leap Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LPTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LPTX

Analyst Price Target is $11.38
▲ +255.47% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Leap Therapeutics in the last 3 months. The average price target is $11.38, with a high forecast of $17.50 and a low forecast of $7.00. The average price target represents a 255.47% upside from the last price of $3.20.

This chart shows the closing price for LPTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Leap Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/19/2024HC WainwrightReiterated RatingBuy ➝ Buy$7.00Low
3/19/2024Robert W. BairdLower TargetOutperform ➝ Outperform$11.00 ➝ $9.00Low
11/20/2023MizuhoLower TargetBuy ➝ Buy$20.00 ➝ $12.00Low
11/14/2023Raymond JamesLower TargetOutperform ➝ Outperform$18.50 ➝ $17.50Low
8/15/2023HC WainwrightBoost TargetBuy ➝ Buy$7.00Low
8/15/2023Robert W. BairdLower TargetOutperform ➝ Outperform$30.00 ➝ $20.00Low
6/23/2023Raymond JamesLower Target$20.00 ➝ $17.00Low
4/13/2023MizuhoReiterated RatingBuy$20.00Low
3/17/2023MizuhoLower TargetBuy$30.00 ➝ $20.00Low
1/27/2023MizuhoLower TargetBuy$60.00 ➝ $30.00Low
1/18/2023HC WainwrightLower TargetBuy$40.00 ➝ $25.00Low
1/17/2023Piper SandlerLower Target$40.00 ➝ $30.00Low
11/21/2022Robert W. BairdLower Target$40.00Low
11/11/2022Raymond JamesLower TargetOutperform$35.00 ➝ $25.00Low
8/15/2022Raymond JamesBoost TargetOutperform$30.00 ➝ $35.00Low
7/13/2022Raymond JamesLower TargetOutperform$40.00 ➝ $30.00Low
5/27/2022Piper SandlerLower Target$60.00 ➝ $40.00Low
11/15/2021HC WainwrightReiterated RatingBuy$40.00Low
10/22/2021MizuhoReiterated RatingBuy$60.00Low
10/4/2021MizuhoInitiated CoverageBuy$60.00Medium
9/13/2021Raymond JamesBoost TargetOutperform$30.00 ➝ $40.00Low
5/17/2021Piper SandlerLower TargetOverweight$60.00 ➝ $40.00Low
3/23/2021Raymond JamesSet TargetOutperform$35.00Medium
3/15/2021Raymond JamesSet TargetOutperform$35.00High
3/2/2021Raymond JamesBoost TargetOutperform$25.00 ➝ $35.00High
12/23/2020Raymond JamesSet TargetOutperform$25.00N/A
11/16/2020Raymond JamesSet TargetOutperform$25.00Low
11/10/2020Raymond JamesSet TargetOutperform$25.00Low
9/22/2020Raymond JamesSet TargetOutperform$25.00Low
8/17/2020Raymond JamesSet TargetOutperform$25.00Medium
8/17/2020HC WainwrightLower TargetBuy$50.00 ➝ $40.00High
7/19/2020LADENBURG THALM/SH SHReiterated RatingMarket Perform ➝ Buy$80.00High
6/29/2020Piper SandlerInitiated CoverageOverweight$60.00High
6/12/2020Raymond JamesSet TargetOutperform$25.00High
5/19/2020HC WainwrightReiterated RatingBuy$25.00 ➝ $50.00Medium
5/17/2020Raymond JamesSet TargetOutperform$25.00Medium
4/24/2020Raymond JamesSet TargetOutperform$25.00Low
3/17/2020Raymond JamesSet TargetOutperform$25.00Low
3/17/2020HC WainwrightLower TargetBuy$32.50 ➝ $25.00High
2/10/2020Robert W. BairdInitiated CoverageOutperform$60.00High
1/8/2020Raymond JamesUpgradeMarket Perform ➝ Outperform$25.00Low
11/15/2019HC WainwrightReiterated RatingBuy$32.50High
11/15/2019Raymond JamesDowngradeOutperform ➝ Market PerformHigh
9/19/2019Raymond JamesSet TargetOutperform$50.00Low
9/13/2019Raymond JamesInitiated CoverageOutperform$50.00Medium
(Data available from 4/25/2019 forward)

News Sentiment Rating

0.62 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
12/27/2023
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
1/26/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Leap Therapeutics logo
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Read More

Today's Range

Now: $3.20
Low: $3.11
High: $3.29

50 Day Range

MA: $2.76
Low: $2.14
High: $3.41

52 Week Range

Now: $3.20
Low: $1.24
High: $10.20

Volume

206,970 shs

Average Volume

315,677 shs

Market Capitalization

$81.92 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.57

Frequently Asked Questions

What sell-side analysts currently cover shares of Leap Therapeutics?

The following Wall Street analysts have issued stock ratings on Leap Therapeutics in the last twelve months: HC Wainwright, Mizuho, Raymond James, and Robert W. Baird.
View the latest analyst ratings for LPTX.

What is the current price target for Leap Therapeutics?

4 Wall Street analysts have set twelve-month price targets for Leap Therapeutics in the last year. Their average twelve-month price target is $11.38, suggesting a possible upside of 253.3%. Raymond James has the highest price target set, predicting LPTX will reach $17.50 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $7.00 for Leap Therapeutics in the next year.
View the latest price targets for LPTX.

What is the current consensus analyst rating for Leap Therapeutics?

Leap Therapeutics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LPTX will outperform the market and that investors should add to their positions of Leap Therapeutics.
View the latest ratings for LPTX.

What other companies compete with Leap Therapeutics?

Other companies that are similar to Leap Therapeutics include Affimed, LifeVantage, Chimerix, Q32 Bio and Aileron Therapeutics. Learn More about companies similar to Leap Therapeutics.

How do I contact Leap Therapeutics' investor relations team?

Leap Therapeutics' physical mailing address is 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE MA, 02141. The company's listed phone number is (617) 714-0360 and its investor relations email address is [email protected]. The official website for Leap Therapeutics is www.leaptx.com. Learn More about contacing Leap Therapeutics investor relations.